CYP2C19 Genotype Is Associated With Adverse Cardiovascular Outcomes in Black Patients Treated With Clopidogrel Undergoing Percutaneous Coronary Intervention

MLA

Kayla R. Tunehag, et al. “CYP2C19 Genotype Is Associated With Adverse Cardiovascular Outcomes in Black Patients Treated With Clopidogrel Undergoing Percutaneous Coronary Intervention.” Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, vol. 13, no. 12, June 2024. EBSCOhost, https://doi.org/10.1161/JAHA.123.033791.

APA

Kayla R. Tunehag, Cameron D. Thomas, Francesco Franchi, Joseph S. Rossi, Ellen C. Keeley, R. David Anderson, Amber L. Beitelshees, Julio D. Duarte, Yan Gong, Richard A. Kerensky, Caitrin W. McDonough, Anh B. Nguyen, Luis Ortega‐Paz, Sanjay Venkatesh, Yehua Wang, Julie A. Johnson, Almut G. Winterstein, George A. Stouffer, Dominick J. Angiolillo, … Craig R. Lee. (2024). CYP2C19 Genotype Is Associated With Adverse Cardiovascular Outcomes in Black Patients Treated With Clopidogrel Undergoing Percutaneous Coronary Intervention. Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 13(12). https://doi.org/10.1161/JAHA.123.033791

Chicago

Kayla R. Tunehag, Cameron D. Thomas, Francesco Franchi, Joseph S. Rossi, Ellen C. Keeley, R. David Anderson, Amber L. Beitelshees, et al. 2024. “CYP2C19 Genotype Is Associated With Adverse Cardiovascular Outcomes in Black Patients Treated With Clopidogrel Undergoing Percutaneous Coronary Intervention.” Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease 13 (12). doi:10.1161/JAHA.123.033791.